Education
About Us
Working with TipRanks
Follow Us
Dermata Therapeutics (DRMA)
NASDAQ:DRMA
DRMA Stock Chart & Stats
$3.04
-$0.06(-4.41%)
At close: 4:00 PM EST
$3.04
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$2.90 - $23.70
Previous CloseN/A
Volume28.34K
Average Volume (3M)249.42K
Market Cap
$2.09M
Enterprise Value-$475.87K
Total Cash (Recent Filing)$6.48M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 18, 2025EPS Estimate
-1.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding681,557
10 Day Avg. Volume611,626
30 Day Avg. Volume249,418
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap-0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$10.00Price Target Upside228.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsDRMA announced positive topline results from its first pivotal Phase 3 trial of XYNGARI, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne.
Product EfficacyXYNGARI demonstrated a statistically significant difference from placebo on three efficacy endpoints as early as week 4, indicating rapid efficacy.
Regulatory StrategyThe strategic shift toward the FDA OTC monograph pathway is seen as a prudent move that should reduce time to market, regulatory hurdles, and capital requirements for commercializing Spongilla technology.
Bears Say
Capital RequirementsThe company will need to raise substantial additional capital or enter into a strategic partnership or licensing agreements to support a second Phase 3 trial.
Financial ChallengesThe company is pre-revenue and is expected to require a capital raise before the end of 2025.
Share Price TargetExpected share dilution from anticipated capital raises to support clinical initiatives has led to a lowered 12-month price target to $10.00.
Dermata Therapeutics News
DRMA FAQ
What was Dermata Therapeutics’s price range in the past 12 months?
Dermata Therapeutics lowest stock price was $2.90 and its highest was $23.70 in the past 12 months.
What is Dermata Therapeutics’s market cap?
Dermata Therapeutics’s market cap is $2.09M.
When is Dermata Therapeutics’s upcoming earnings report date?
Dermata Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 9 days.
How were Dermata Therapeutics’s earnings last quarter?
Dermata Therapeutics released its earnings results on Aug 13, 2025. The company reported -$1.66 earnings per share for the quarter, beating the consensus estimate of -$2.9 by $1.24.
Is Dermata Therapeutics overvalued?
According to Wall Street analysts Dermata Therapeutics’s price is currently Undervalued.
Does Dermata Therapeutics pay dividends?
Dermata Therapeutics does not currently pay dividends.
What is Dermata Therapeutics’s EPS estimate?
Dermata Therapeutics’s EPS estimate is -1.59.
How many shares outstanding does Dermata Therapeutics have?
Dermata Therapeutics has 681,557 shares outstanding.
What happened to Dermata Therapeutics’s price movement after its last earnings report?
Dermata Therapeutics reported an EPS of -$1.66 in its last earnings report, beating expectations of -$2.9. Following the earnings report the stock price went down -9.783%.
Which hedge fund is a major shareholder of Dermata Therapeutics?
Currently, no hedge funds are holding shares in DRMA
Company Description
Dermata Therapeutics
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
DRMA Stock 12 Month Forecast
Average Price Target
$10.00
▲(228.95% Upside)
Technical Analysis
NLS Pharmaceutics
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―